If the proposed rule is finalized, it will impose the regulatory controls and criminal sanctions of schedule IV on anyone who handles propofol and products containing the drug.
According to an ASA news release, “ASA hopes that the tighter controls and monitoring that accompany scheduling will reduce the potential for abuse, although we recognize that such action will not completely prevent all problems associated with the misuse of propofol.”
Comments on the proposed rule are due Dec. 27.
Read the ASA news release about the proposed propofol scheduling.
View the Federal Register notice about the proposed rule for propofol (pdf).
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
